Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
• Safety Review Committee endorses escalation to 160 mg TUS dosing; no dose-limiting toxicities to date
Could the positive safety committee endorsement trigger short‑term trading activity or short‑covering dynamics in the market?
What is the anticipated impact on the company's valuation multiples (e.g., EV/EBITDA, price‑to‑sales) given this trial progression?
How might the safety profile of the 160 mg dose affect future dose‑selection decisions for later‑stage trials and overall trial design?
Symbol:
APTO
22 days ago